

# Matthias Klinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1181592/publications.pdf>

Version: 2024-02-01

13  
papers

3,364  
citations

840776

11  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

3304  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. Annual Review of Cancer Biology, 2022, 6, 17-34.	4.5	23
2	Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab. Experimental Hematology, 2021, 100, 32-36.	0.4	3
3	CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab. Pediatric Blood and Cancer, 2021, 68, e29323.	1.5	8
4	Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events. Cancer Research, 2020, 80, 91-101.	0.9	54
5	Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma. Current Clinical Pharmacology, 2018, 13, 55-64.	0.6	19
6	Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica, 2017, 102, e132-e135.	3.5	81
7	Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. Experimental Hematology and Oncology, 2017, 6, 14.	5.0	60
8	Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Journal of Clinical Oncology, 2016, 34, 1104-1111.	1.6	359
9	Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood, 2015, 126, 2578-2584.	1.4	136
10	Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood, 2012, 119, 6226-6233.	1.4	410
11	Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood, 2012, 120, 5185-5187.	1.4	435
12	Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival. Journal of Clinical Oncology, 2011, 29, 2493-2498.	1.6	819
13	Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody. Science, 2008, 321, 974-977.	12.6	957